Skip to main content
SpringerLink
Log in

Jede schmerzlose Makrohämaturie ernst nehmen

Harnblasenkrebs: frühe Detektion essenziell für die erfolgreiche Therapie

Diagnosis and therapy of bladder cancer

  • FORTBILDUNG_ÜBERSICHTEN
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Das Harnblasenkarzinom ist die häufigste bösartige Erkrankung des unteren Harntrakts. Klassisches Symptom ist die schmerzlose Makrohämaturie, die Sie in jedem Fall ernst nehmen sollten. Über den aktuellen Stand bei Diagnostik und Therapie informiert Sie der nachfolgende Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European urology. 2013; 64(4): 639–53.

    Article  PubMed  Google Scholar 

  2. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. International journal of surgical pathology. 2005; 13(2): 143–53.

    Article  PubMed  Google Scholar 

  3. Grossfeld GD, Wolf JS, Jr., Litwan MS, Hricak H, Shuler CL, Agerter DC, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. American family physician. 2001; 63(6): 1145–54.

    CAS  PubMed  Google Scholar 

  4. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. The Journal of urology. 2010; 184(5): 1907–13.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354(9178): 533-40.

  6. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European urology. 2005; 48(2): 202-5; discussion 5-6.

  7. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. European urology. 2014; 65(4): 778–92.

    Article  PubMed  Google Scholar 

  8. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2014; 25 Suppl 3: iii40–8.

  9. Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. European urology. 2012; 61(5): 1070–1.

    Article  PubMed  Google Scholar 

  10. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. European urology. 2014; 66(1): 42–54.

    Article  CAS  PubMed  Google Scholar 

  11. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(21): 4602–8.

  12. Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013; 24(6): 1466–72.

    Article  CAS  Google Scholar 

  13. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528): 558–62.

    Article  CAS  PubMed  Google Scholar 

  14. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20(14): 3061–71.

  15. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(34): 3801–9.

Download references

Author information

Authors and Affiliations

  1. Klinikum der Ludwig-Maximilians-Universität München, Abteilung für Urologie, Marchioninistr. 15, D-81377, München, Deutschland

    Jan-Friedrich Jokisch

  2. Klinikum Ludwig-Maximilians-Universität, Campus Großhadern, Abteilung für Strahlentherapie und Radioonkologie, München, Deutschland

    Ute Ganswindt

  3. Rotkreuzklinikum München, München, Deutschland

    Marcus Hentrich

  4. Klinikum Ludwig-Maximilians-Universität, Campus Großhadern, Abteilung für Urologie, München, Deutschland

    Christian Stief &  Alexander Karl

Authors
  1. Jan-Friedrich Jokisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ute Ganswindt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcus Hentrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander Karl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan-Friedrich Jokisch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jokisch, JF., Ganswindt, U., Hentrich, M. et al. Harnblasenkrebs: frühe Detektion essenziell für die erfolgreiche Therapie. MMW - Fortschritte der Medizin 157, 42–46 (2015). https://doi.org/10.1007/s15006-015-7539-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-7539-4

Keywords

Search

Navigation